The full-year consolidated results for the fiscal year ending March 2026 show net sales of 300,090 million yen, operating profit of 12,527 million yen, and net income attributable to owners of the parent of 1,713 million yen. Sales exceeded forecasts, but net income decreased. The increase in tax expenses due to impairment losses led to net income falling short of expectations.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7616","jir_company_name":"Unknown","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/7616-20260508-02.pdf","jir_short_summary":"The full-year consolidated results for the fiscal year ending March 2026 show net sales of 300,090 million yen, operating profit of 12,527 million yen, and net income attributable to owners of the parent of 1,713 million yen. Sales exceeded forecasts, but net income decreased. The increase in tax expenses due to impairment losses led to net income falling short of expectations.","jir_summary":"### Performance Overview\nThe consolidated net sales for the fiscal year ending March 2026 were 300,090 million yen, surpassing expectations, but net income was 1,713 million yen, falling short of projections. The recording of impairment losses and the reversal of deferred tax assets increased corporate tax burdens, leading to a decrease in net income. Sales increased by 4.0% YoY, and operating profit rose by 10.8%, but net income decreased by approximately 47.6%.\n\n### Future Outlook and Impact on Shareholders\nAlthough temporary profit pressure resulted from recording impairment losses, sales are trending steadily. Considering the increased tax burden and loss recognition, strategic measures are needed to improve future performance. Investors can expect a recovery in profits alongside sales growth, but should also remain cautious of short-term profit pressures.","jir_financial_highlights":"Net Sales: 300,090 million yen (YoY +11,663 million yen (+4.0%))\nOperating Profit: 12,527 million yen (YoY +1,226 million yen (+10.8%))\nNet Income Attributable to Owners of the Parent: 2,233 million yen (YoY +103 million yen (+4.9%))","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #FinancialResults, #JapaneseStocks","jir_key_figures":"Net Sales: 300,090 million yen (YoY +4.0%)\nOperating Profit: 12,527 million yen (YoY +10.8%)\nNet Income Attributable to Owners of the Parent: 2,233 million yen (YoY +4.9%)","jir_meta_title":"Takeda Pharmaceutical 2026 Fiscal Year Results\uff5cSteady Sales but Decline in Net Income","jir_meta_description":"The 2026 fiscal year consolidated results exceeded estimates with net sales of 300,090 million yen, but net income declined. Impacts from impairment losses and increased tax burdens are noted.","jir_og_title":"Takeda Pharmaceutical 2026 Fiscal Year Results\uff5cSteady Sales but Decline in Net Income","jir_og_description":"The 2026 fiscal year results show sales exceeding forecasts but net income decreasing. Attention is on future performance trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9050,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-45992","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n